Results 21 to 30 of about 1,927 (159)
Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
Annals of Clinical and Translational Neurology, 2021 Objective Human T‐cell lymphotropic virus 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive myelopathy. A high proviral load (PVL) is one of the main risk factors for HAM/TSP.
Yoshimi Enose‐Akahata +10 more
doaj +1 more source
Frontiers in Cellular and Infection Microbiology, 2023 IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings.
José Ramón Santos +64 more
doaj +1 more source
Effects of Omeprazole on Plasma Levels of Raltegravir [PDF]
Clinical Infectious Diseases, 2009 Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent solubility. Raltegravir plasma concentration increases with omeprazole coadministration in healthy subjects; this is likely secondary to an increase in bioavailability attributable to increased gastric pH.
Julie A. Stone +15 more
openaire +3 more sources
Microbiology Spectrum, 2022 To ensure the long-term efficacy of dolutegravir (DTG), we evaluated the genotypic profile in viral reservoirs among patients on third-line (3L) antiretroviral therapy (ART) in Cameroon, according to prior exposure to raltegravir (RAL).
Joseph Fokam +31 more
doaj +1 more source
Features of application of raltegravir in HIV-infected patients with different somatic pathologies
Журнал инфектологии, 2021 Purpose of the study. Evaluation of the efficacy, safety and tolerability of raltegravir regimens in HIV-infected patients with concomitant pathology in real clinical practice.Materials and methods.
N. V. Sizova +2 more
doaj +1 more source
Dissolution Enhancement of Raltegravir by Hot Melt Extrusion Technique
Iraqi Journal of Pharmaceutical Sciences, 2018 The objective of the study to develop an amorphous solid dispersion for poorly soluble raltegravir by hot melt extrusion (HME) technique. A novel solubility improving agent plasdone s630 was utilized.
Ahmed S. Abdul Jabbar
doaj +1 more source
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir [PDF]
Antimicrobial Agents and Chemotherapy, 2015 ABSTRACT Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir.
Aurélie Barrail-Tran +8 more
openaire +3 more sources
PLoS ONE, 2019 Antiretroviral agents are approved in Japan based on non-clinical and clinical data reported from overseas. Neither the long-term tolerability nor the effectiveness of raltegravir or other integrase strand transfer inhibitors in Japan is known.
Naho Kuroishi +4 more
doaj +1 more source
PLoS ONE, 2014 To characterize the HIV-2 integrase gene polymorphisms and the pathways to resistance of HIV-2 patients failing a raltegravir-containing regimen, we studied 63 integrase strand transfer inhibitors (INSTI)-naïve patients, and 10 heavily pretreated ...
Joana Cavaco-Silva +14 more
doaj +1 more source
Frontiers in Pharmacology, 2019 Background: The life expectancy for HIV-infected individuals has improved dramatically because of improvements in antiretroviral therapy (ART). Today, a simplified two-drug regimen enhances adherence and treatment satisfaction by reducing adverse effects.
Yinqiu Huang +6 more
doaj +1 more source